1. Short title This Act may be cited as the Commission on America’s Medical Security Act . 2. National Academies report on America’s medical product supply chain security (a) In general Not later than 60 days after the date of enactment of this Act, the Secretary of Health and Human Services shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the National Academies ) to examine, and, in a manner that does not compromise national security, report on, the security of the United States medical product supply chain. (b) Purposes The report developed under this section shall— (1) assess and evaluate the dependence of the United States, including the private commercial sector, States, and the Federal Government, on critical drugs and devices that are sourced or manufactured outside of the United States, which may include an analysis of— (A) the supply chain of critical drugs and devices of greatest priority to providing health care; (B) any potential public health security or national security risks associated with reliance on critical drugs and devices sourced or manufactured outside of the United States, which may include responses to previous or existing shortages or public health emergencies, such as infectious disease outbreaks, bioterror attacks, and other public health threats; (C) any existing supply chain information gaps, as applicable; and (D) potential economic impact of increased domestic manufacturing; and (2) provide recommendations, which may include a plan to improve the resiliency of the supply chain for critical drugs and devices as described in paragraph (1), and to address any supply vul­ner­a­bil­i­ties or potential disruptions of such products that would significantly affect or pose a threat to public health security or national security, as appropriate, which may include strategies to— (A) promote supply chain redundancy and contingency planning